Studio Calesini · Via della Croce 77, Rome
A clinical protocol for guided bone and soft tissue regeneration around implants, developed in Rome and documented in indexed scientific literature. What it involves, what it can achieve, and where its limits lie.
Morphogenic Tissue Management (MTM) is a clinical protocol for the guided regeneration of bone and peri-implant soft tissue. It was developed in Rome in the 1990s by Dr. Gaetano Calesini and Dr. Scipioni, and has been documented through articles published in indexed scientific journals and a monographic text published by Quintessenza Internazionale. The protocol is not a product or a device: it is a systematic approach to tissue management that governs surgical timing, implant positioning, loading protocols, and prosthetic design in relation to the biological behaviour of the tissues being managed.
Dental implant placement in sites with reduced bone volume or compromised soft tissue has historically required preliminary bone grafting procedures, healing intervals, and a sequence of staged interventions extending over one to two years before the final prosthetic result could be achieved. Grafting procedures introduce additional surgical morbidity, depend on donor site availability or synthetic materials, and carry the risk of partial or complete resorption.
The underlying clinical question that motivated the development of MTM was whether bone regeneration could be guided through the controlled management of biological signals, the morphogenic factors present in the surgical wound, rather than through the mechanical insertion of grafting material. The protocol emerged from the hypothesis that the biological environment itself, properly managed, contains the regenerative capacity required for the clinical outcome.
The protocol is built on the principle that biological signals present in the wound, growth factors, bone morphogenetic proteins, and cells capable of osteogenic differentiation, can be preserved and directed through surgical technique rather than supplemented by exogenous materials. The surgical approach is designed to minimise disruption of the periosteal envelope and protect the biological environment of the implant site.
The three-dimensional positioning of the implant is a functional variable in MTM, not only a prosthetic one. The relationship between the implant platform and the adjacent bone crest determines the biological response at the interface. MTM specifies positioning criteria designed to maintain the coronal bone level and promote the formation of a stable peri-implant tissue architecture over time.
The timing and method of prosthetic loading are variables that influence the biology of osseointegration and tissue maturation. MTM includes specific loading protocols calibrated to the regenerative stage of the peri-implant tissues, avoiding mechanical interference at phases where the biological process is most vulnerable.
The provisional and definitive prosthetic components are not designed independently of the tissue management process. In MTM, prosthetic contours, emergence profiles, and occlusal contacts are planned in direct relation to the tissue architecture being developed, and are modified progressively as tissue maturation proceeds.
The MTM protocol has been applied to cases involving deficient bone volume in both vertical and horizontal dimensions, peri-implant defects following implant failure, and sites requiring soft tissue management for aesthetic peri-implant outcomes. The documented outcomes include bone fill in sites where grafting would conventionally have been the first-line approach, and stable soft tissue architecture in cases where loss of the interdental papilla or buccal tissue volume would have been expected.
It is equally important to state what MTM does not claim. The regenerative capacity of biological tissue is finite and site-dependent. In sites with severe bone atrophy, previous irradiation, uncontrolled systemic disease, or compromised vascular supply, the regenerative environment is insufficient to support a graft-free approach regardless of the surgical protocol applied. Patient selection and clinical assessment are prerequisites for any decision regarding the appropriateness of the protocol in a given case.
MTM is not applicable to all implant cases, and it is not a substitute for the clinical assessment that determines whether a graft-free or graft-assisted approach is the correct choice for a specific patient.
The MTM protocol has been presented and documented through peer-reviewed publications in indexed dental journals and through a monographic text published by Quintessenza Internazionale, one of the principal scientific publishers in European prosthodontics and implantology. The protocol has been presented at national and international congresses and has been incorporated into postgraduate training programmes in implant prosthetics.
The clinical cases supporting the protocol represent outcomes documented over multiple years of follow-up, reflecting the long-term stability requirements that distinguish a documented protocol from a clinical innovation at the case-report level.
PubMed · peer-reviewed publications
The full description of the protocol, its clinical indications and the scientific documentation are collected on the official website dedicated to MTM:
implantologia-biomimetica.com
Official MTM protocol website · IT / EN
The suitability of MTM for a given case requires clinical and radiographic assessment. The protocol is not applied as a default alternative to grafting: it is applied where the assessment indicates that the biological conditions are appropriate.
Assessment at Studio Calesini
Dr. Gaetano Calesini evaluates cases requiring implant placement in compromised bone sites, cases following implant failure with associated bone loss, and cases where conventional bone grafting has been proposed but the patient seeks an independent assessment of available options. The consultation includes complete clinical and radiographic review and a written treatment plan with clinical rationale. Italian, English, and any language via AI-assisted communication.
No. MTM is applicable in cases where the biological environment retains sufficient regenerative capacity and the clinical assessment confirms that a graft-free approach is feasible. Cases with severe atrophy, systemic conditions that impair healing, or sites with compromised vascular supply may require bone grafting regardless of the surgical protocol considered. Patient selection is a prerequisite.
The MTM protocol was developed in Rome in the 1990s by Dr. Gaetano Calesini and Dr. Scipioni. It has been documented in peer-reviewed publications in indexed scientific journals and in a monographic text published by Quintessenza Internazionale. Dr. Calesini continues to apply and refine the protocol at Studio Calesini in Rome.
Guided bone regeneration (GBR) uses barrier membranes to exclude non-osteogenic cells from the regenerating site and typically involves the placement of grafting material to provide a scaffold. MTM seeks to direct the morphogenic signals present in the surgical wound without the routine addition of exogenous grafting material. The two approaches are not mutually exclusive, and in selected cases may be combined, but they proceed from different biological premises.
It depends on the condition of the site following the failed graft. Where residual bone volume and tissue vascularity are adequate, and systemic factors have been addressed, the site may be assessed for a graft-free approach. Each case requires individual clinical and radiographic evaluation.